
News|Articles|July 8, 2026
First Half 2026 Recap: Nephrology
Author(s)Alex Hillenbrand
Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 marked a transformative period in nephrology, with landmark regulatory approvals, evolving clinical practice guidelines, and pivotal phase 3 trial results accelerating a shift toward precision medicine and disease modification. Across
Related to this article

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.

HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Advertisement
Advertisement
